Physician profile
John Beckner
NPI 1538212519
$5,526.67
in general payments reported to CMS, 2019-2025
28 companies · $1,818 in 2025
The $1,818 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $565 · 2021: $643 · 2023: $323 · 2024: $1,263 · 2025: $1,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,403.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $754.24 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $712.43 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $608.21 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $551.92 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $550.15 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $407.65 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $344.21 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $310.40 | 2019-2025 | Trintellix |
| Alkermes, INC. | $223.66 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Allergan, INC. | $176.27 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $167.53 | 2019-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $111.49 | 2019-2020 | |
| Luye Pharma (USA) Ltd. | $81.12 | 2025 | Erzofri Extended-Release |
| Merck Sharp & Dohme LLC | $65.65 | 2019-2021 | |
| Axsome Therapeutics, INC. | $61.73 | 2024-2025 | Auvelity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $58.13 | 2023-2024 | Jornay Pm |
| Almatica Pharma LLC | $54.73 | 2023-2025 | Loreev Xr |
| Neuronetics, INC. | $52.58 | 2019-2020 | |
| Brainsway USA INC | $52.04 | 2019-2024 | Brainsway Deep Tms System |
| Biogen, INC. | $29.52 | 2024 | |
| Eisai INC. | $26.26 | 2021 | |
| Harmony Biosciences LLC | $24.67 | 2025 | |
| Jazz Pharmaceuticals INC. | $20.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.99 | 2025 | Cobenfy |
| Novartis Pharmaceuticals Corporation | $16.57 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.83 | 2025 | Jornay Pm |
| Shire North American Group INC | $14.56 | 2019 | |
| Adlon Therapeutics L.P. | $14.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Beckner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.